{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:40:39Z","timestamp":1773218439612,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1476-511x-12-103","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T12:14:32Z","timestamp":1373976872000},"source":"Crossref","is-referenced-by-count":6,"title":["Consistency of effect of ezetimibe\/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects"],"prefix":"10.1186","volume":"12","author":[{"given":"Jeffrey B.","family":"Rosen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose G.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valdis","family":"Pirags","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hella","family":"Vides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Massaad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Brudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Triscari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,16]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234. 10.1056\/NEJM199807233390404","journal-title":"N Engl J Med"},{"key":"938_CR2","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJM199812033392314","volume":"339","author":"LA Simons","year":"1998","unstructured":"Simons LA, Simons J: Diabetes and coronary heart disease. N Engl J Med. 1998, 339: 1714-1715.","journal-title":"N Engl J Med"},{"key":"938_CR3","doi-asserted-by":"crossref","unstructured":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr. 1998, 68: 899-917.","DOI":"10.1093\/ajcn\/68.4.899"},{"key":"938_CR4","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert panel on detection evaluation and treatment of high blood cholesterol in adults","year":"2001","unstructured":", : Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001\/jama.285.19.2486","journal-title":"JAMA"},{"issue":"25","key":"938_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0828-282X(09)70715-9","volume":"2009","author":"J Genest","year":"2009","unstructured":"Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E: Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009, 2009 (25): 567-579.","journal-title":"Can J Cardiol"},{"key":"938_CR6","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/01.hjr.0000277984.31558.c4","volume":"14","author":"Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice","year":"2007","unstructured":", : European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil. 2007, 14: E1-E40. 10.1097\/01.hjr.0000277984.31558.c4","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"938_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/187153007781662567","volume":"7","author":"MR Hoenig","year":"2007","unstructured":"Hoenig MR, Kostner KM, Read SJ, Walker PJ, Atherton JJ: Implications of the obesity epidemic for statin therapy: shifting cholesterol metabolism to a high synthesis and low dietary absorption state. Endocr Metab Immune Disord Drug Targets. 2007, 7: 153-166. 10.2174\/187153007781662567","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"938_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0889-8529(03)00073-2","volume":"32","author":"BV Howard","year":"2003","unstructured":"Howard BV, Ruotolo G, Robbins DC: Obesity and dyslipidemia. Endocrinol Metab Clin North Am. 2003, 32: 855-867. 10.1016\/S0889-8529(03)00073-2","journal-title":"Endocrinol Metab Clin North Am"},{"key":"938_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2337\/dc08-9018","volume":"31","author":"JD Brunzell","year":"2008","unstructured":"Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL: Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008, 31: 811-822. 10.2337\/dc08-9018","journal-title":"Diabetes Care"},{"key":"938_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1475-2840-9-20","volume":"9","author":"G Bardini","year":"2010","unstructured":"Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM: Ezetimibe\u2009+\u2009simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol. 2010, 9: 20- 10.1186\/1475-2840-9-20","journal-title":"Cardiovasc Diabetol"},{"key":"938_CR11","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.4065\/81.12.1579","volume":"81","author":"RB Goldberg","year":"2006","unstructured":"Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, Tomassini JE, Tershakovec AM: Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc. 2006, 81: 1579-1588. 10.4065\/81.12.1579","journal-title":"Mayo Clin Proc"},{"key":"938_CR12","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/j.1742-1241.2010.02429.x","volume":"64","author":"T McCormack","year":"2010","unstructured":"McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P: Incremental cholesterol reduction with ezetimibe\/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract. 2010, 64: 1052-1061. 10.1111\/j.1742-1241.2010.02429.x","journal-title":"Int J Clin Pract"},{"key":"938_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1463-1326.2011.01383.x","volume":"13","author":"LA Leiter","year":"2011","unstructured":"Leiter LA, Betteridge DJ, Farnier M, Guyton JR, Lin J, Shah A, Johnson-Levonas AO, Brudi P: Lipid-altering efficacy and safety profile of combination therapy with ezetimibe\/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab. 2011, 13: 615-628. 10.1111\/j.1463-1326.2011.01383.x","journal-title":"Diabetes Obes Metab"},{"key":"938_CR14","first-page":"277","volume":"10","author":"JB Rosen","year":"2012","unstructured":"Rosen JB, Jimenez JG, Pirags V, Vides H, Hanson ME, Massaad R, McPeters G, Brudi P, Triscari J: A comparison of efficacy and safety of an ezetimibe\/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Cardiovasc Drugs Ther. 2012, 10: 277-286.","journal-title":"Cardiovasc Drugs Ther"},{"key":"938_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13556-011-0001-8","volume":"1","author":"L Missault","year":"2011","unstructured":"Missault L, Averna M, Farnier M, Vaverkova H, Viikari J, Dong Q, Shah A, Johnson-Levonas A, Taggart W, Brudi P: Efficacy of Ezetimibe\/Simvastatin 10\/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity. Combination Products in Therapy. 2011, 1: 1-15.","journal-title":"Combination Products in Therapy"},{"key":"938_CR16","first-page":"538","volume":"17","author":"A Furman","year":"2011","unstructured":"Furman A, Meier JL, Malmstrom RA, Lopez JR, Schaefer S: Comparative efficacy of ezetimibe\/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients. Am J Manag Care. 2011, 17: 538-544.","journal-title":"Am J Manag Care"},{"key":"938_CR17","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.2337\/diacare.25.9.1511","volume":"25","author":"PP Simonen","year":"2002","unstructured":"Simonen PP, Gylling HK, Miettinen TA: Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care. 2002, 25: 1511-1515. 10.2337\/diacare.25.9.1511","journal-title":"Diabetes Care"},{"key":"938_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.amjcard.2005.08.038","volume":"97","author":"MH Davidson","year":"2006","unstructured":"Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T: Striated muscle safety of ezetimibe\/simvastatin (Vytorin). Am J Cardiol. 2006, 97: 223-228. 10.1016\/j.amjcard.2005.08.038","journal-title":"Am J Cardiol"},{"key":"938_CR19","volume-title":"FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury","author":"US Food and Drug Administration","year":"2013","unstructured":", : FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 2013, Silver Springs, MD: US Department of Health & Human Services."}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-511X-12-103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1476-511X-12-103\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-511X-12-103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:51:28Z","timestamp":1548204688000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/1476-511X-12-103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,16]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1186\/1476-511x-12-103","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,16]]},"article-number":"103"}}